263 related articles for article (PubMed ID: 22503591)
1. Alternatives to indicating roflumilast and the chronic obstructive pulmonary disease classification.
Blasco LM
Arch Bronconeumol; 2012 Sep; 48(9):343. PubMed ID: 22503591
[No Abstract] [Full Text] [Related]
2. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
Martínez FJ
Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
[No Abstract] [Full Text] [Related]
3. [Phosphodiesterase-4 inhibitors: roflumilast].
Izquierdo Alonso JL
Rev Clin Esp; 2011 Mar; 211 Suppl 2():22-30. PubMed ID: 21596170
[TBL] [Abstract][Full Text] [Related]
4. Roflumilast (Daliresp) for COPD.
Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
[No Abstract] [Full Text] [Related]
5. [Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
Sinopal'nikov AI
Klin Med (Mosk); 2014; 92(2):57-64. PubMed ID: 25269184
[TBL] [Abstract][Full Text] [Related]
6. Roflumilast, indacaterol maleate, and abiraterone acetate.
Hussar DA; DePasquale J
J Am Pharm Assoc (2003); 2011; 51(5):668-71. PubMed ID: 21896467
[No Abstract] [Full Text] [Related]
7. Roflumilast: doubtful efficacy but clear harms in COPD.
Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
[TBL] [Abstract][Full Text] [Related]
8. [Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
Michels G; Erdmann E; Pfister R
Dtsch Med Wochenschr; 2011 Nov; 136(44):2267-70. PubMed ID: 22028292
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast for chronic obstructive pulmonary disease.
Morice AH
Lancet; 2005 Nov; 366(9500):1845; author reply 1846-7. PubMed ID: 16310544
[No Abstract] [Full Text] [Related]
10. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast for COPD.
Izquierdo JL; Aparicio J
Drugs Today (Barc); 2010 Nov; 46(11):823-31. PubMed ID: 21225021
[TBL] [Abstract][Full Text] [Related]
12. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Mulhall AM; Droege CA; Ernst NE; Panos RJ; Zafar MA
Expert Opin Investig Drugs; 2015; 24(12):1597-611. PubMed ID: 26419847
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast for severe COPD?
Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast: clinical benefit in patients suffering from COPD.
Ulrik CS; Calverley PM
Clin Respir J; 2010 Oct; 4(4):197-201. PubMed ID: 20887341
[TBL] [Abstract][Full Text] [Related]
16. Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.
O'Malley P
Clin Nurse Spec; 2011; 25(4):176-7. PubMed ID: 21654371
[No Abstract] [Full Text] [Related]
17. Phosphodiesterase-4 inhibition in COPD.
O'Byrne PM; Gauvreau G
Lancet; 2009 Aug; 374(9691):665-7. PubMed ID: 19716944
[No Abstract] [Full Text] [Related]
18. [Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].
Kreutzkamp B
Med Monatsschr Pharm; 2010 Jul; 33(7):236-43. PubMed ID: 20687460
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological profile of roflumilast].
Cortijo Gimeno J; Morcillo Sánchez E
Arch Bronconeumol; 2010 Dec; 46 Suppl 10():19-24. PubMed ID: 21316552
[TBL] [Abstract][Full Text] [Related]
20. [COPD and diabetes mellitus. Does pulmonary medication modify blood glucose metabolism?].
MMW Fortschr Med; 2011 Mar; 153(11):17. PubMed ID: 22165624
[No Abstract] [Full Text] [Related]
[Next] [New Search]
